Mylan is launching its latest generic with its partner, South Africa-based Aspen. The companies are introducing their generic of Otsuka’s Myleran (busulfan, 6 mg/ml) injection.
The product is indicated in combination with cyclophosphamide as a conditioning regimen ahead of allogeneic hematopoietic progenitor cell transplantation in patients with chronic myelogenous leukemia. Mylan said that it has one of the largest injectables portfolios in the industry, and is among the leading cancer medicines suppliers by volume in the United States.
Mylan will commercialize the single-dose vial product in the United States. The drug had U.S. market size of roughly $97 million for the 12 months ended Sept. 30, according to IQVIA data.